BJMO - volume 13, issue 8, december 2019
K. Papadimitriou MD, M. Peeters MD, PhD, H. Prenen MD, PhD
This report will focus on some of the key studies in the field of digestive oncology, presented during the 2019 annual ESMO meeting. During the congress, many studies were presented from early phase I to large phase III trials. Different approaches to activate the immune system against tumours as well as PARP and CDK4/6 inhibitors were once more at the centre of interest for different types of cancer and settings.
Read moreBJMO - volume 13, issue 6, october 2019
C. Debeuckelaere MD, L. Triest MD, T. Vandamme MD, B. Van Den Heuvel MD, K. Papadimitriou MD, M. Rasschaert MD, H. Prenen MD, PhD, M. Peeters MD, PhD
For over a decade, oxaliplatin-based adjuvant chemotherapy has been the gold standard for resected early colon cancer. Oxaliplatin is known to cause polyneuropathy, which affects quality of life dramatically. In recent years, there has not been any progress in the development of novel agents to replace oxaliplatin as adjuvant therapy. Consequently, there is a growing interest to investigate whether a shorter course of chemotherapy is sufficient. This article will discuss the history of adjuvant treatment in early-resected colon cancer, the toxicity of oxaliplatin, the results from the IDEA meta-analysis and future prospects.
(BELG J MED ONCOL 2019;13(6):234–239)
Read moreBJMO - volume 13, issue 6, october 2019
C. Debeuckelaere MD, A. Van Goethem MD, G. Maleux MD, PhD, H. Prenen MD, PhD
Percutaneous balloon vertebroplasty (PVP) is an effective treatment for pathological vertebral compression fractures in oncological patients. The procedure is considered safe and the analgesic effect is fast and long lasting. Seeding metastases after PVP are a rare complication. At present, there is no standard of care how to prevent or treat this complication. Further research is necessary to determine preventive measures.
(BELG J MED ONCOL 2019;13(6): 255–257)
Read moreBJMO - volume 13, issue 5, august 2019
M. Peeters MD, PhD, H. Prenen MD, PhD
At ASCO 2019, several clinical trials regarding upper and lower gastro-intestinal tumors were presented.
Read moreBJMO - volume 13, issue 4, june 2019
W. Lybaert MD, H. Prenen MD, PhD, A. Demols MD, PhD, I. Dero MD
At the background of the Golden Gate Bridge with a view on the Pacific Ocean, the annual Gastrointestinal Cancers Symposium was held from 17–19 January 2019 in the Moscone Congress Center in San Francisco, California. The meeting further underlined the invasion of immunotherapy in the treatment landscape of gastrointestinal tumours, both in the upper and lower digestive tract. In addition to immunotherapy, lots of efforts were made in the molecular profiling of gastrointestinal cancers in every possible tumour location, which will hopefully fuel more biomarker-driven medicine in this setting in the near future. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2019;13(4):142–149)
Read moreBJMO - volume 12, issue 8, december 2018
B. Van Den Heuvel MD, M. Rasschaert MD, L. Triest MD, C. Debeuckelaere MD, F. Couturier , K. Papadimitriou MD, H. Prenen MD, PhD, M. Peeters MD, PhD
Although none of the submitted abstracts in the field of gastro-intestinal oncology reached the presidential sessions of ESMO 2018, some practice-changing and promising data were presented especially in the field of immunotherapy. This report summarises the highlights in the field of colorectal, anal and upper digestive tract cancer.
Read moreBJMO - volume 12, issue 4, august 2018
M. Rasschaert MD, L. Triest MD, J. Van den Brande , K. Papadimitriou MD, H. Prenen MD, PhD, M. Peeters MD, PhD
The 2018 annual meeting of the American Society of Oncology (ASCO) was once more hosted in Chicago. Over 40,000 oncologists attended this years’ convention. This report will summarize the highlights from the gastro-intestinal cancer sessions at the meeting.
Read more
Top
